Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL (CARDINAL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03019185
Recruitment Status : Completed
First Posted : January 12, 2017
Last Update Posted : September 28, 2021
Information provided by (Responsible Party):
Reata Pharmaceuticals, Inc.